Kirjoita osake tai kryptovaluutta hakupalkkiin saadaksesi yhteenvedon
Acrux Ltd
ACRAcrux Limited, together with its subsidiaries, engages in the development and commercialization of generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause; Dapsone 5% and Dapsone 7.5% which are gels for the treatment of acne vulgaris; and Prilocaine 2.5% and Lidocaine 2.5%, a topical anaesthetic cream. It is also involved in the development of Efinaconazole, a topical solution used to treat fungal infections of toenails; Nitroglycerin 0.4%, an ointment for the treatment of pain caused by chronic anal fissure; and Acyclovir 5%, a cream for the treatment of cold sores. The company was incorporated in 1998 and is based in West Melbourne, Australia. Address: 103-113, Stanley Street, West Melbourne, VIC, Australia, 3003
Analytics
WallStreetin tavoitehinta
0.35 AUDP/E-suhde
–Osinkotuotto
–Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Avainluvut ACR
Osinkoanalytiikka ACR
Osinkojen kasvu 5 vuoden aikana
–Jatkuva kasvu
–Maksusuhde 5 vuoden keskiarvo
–Osinkohistoria ACR
Osakkeen arvostus ACR
Talousasiat ACR
Tuloksia | 2019 | Dynamiikka |